WuXi Biologics Reports Strong 2022 Interim Results

Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2...

Related Keywords

Germany ,Shanghai ,China ,Wuppertal ,Nordrhein Westfalen ,United States ,Wuxi ,Jiangsu ,New Jersey ,Singapore ,Cranbury ,Dundalk ,Louth ,Ireland ,Hebei ,Jilin ,Hangzhou ,Zhejiang ,America ,Chinese ,Evusheld Tixagevimab ,Chris Chen ,Us Bureau Of Industry ,Shareholders Of The Company ,Manufacturing Organization ,Wuxi Biologics Cayman Inc ,Astrazeneca ,Group Global Dual ,China Ministry Of Commerce ,Contract Research ,Drug Product Services Generate New Growth ,Us Department Of Commerce Unverified List ,Wuxi Biologics Co Ltd ,Company For The Reporting Period ,Us Department Of Commerce ,Revenue Increased ,Profit Increased ,Profit Grew ,Net Profit Rose ,Model Led Sustainable Long Term ,Drove Significant Revenue ,Integrated Projects ,Commercial Manufacturing Revenue Increased ,Strong Growth Driver ,Allowed Delivery ,Projects Without ,Chain Optimized ,Safeguard Project Execution ,Quality System Re Verified ,Fuel Future ,Talent Pool Expanded ,Support Business ,Start Any Project ,Wuxi Biologics ,Reporting Period ,Net Profit Attributable ,Net Profit ,Business Continuity Plan ,Drug Product ,Pfizer China ,Industry Top Rated Company ,Low Risk ,Businesses Performed ,Progress Made Regarding ,Unverified List ,Demonstrated Strong Operational ,Business Continuity ,Growth Seen ,Wuxi Vaccines ,Both Biotech ,Wuxi Biologics Suzhou ,Talent Pool ,Support Robust Business ,Technology Platforms Enhanced ,Underpin Future ,Standards Met ,Premier Quality ,Business Strategy ,North America ,Wuxi Bio Speed ,Wuxi Bio ,Global Dual Sourcing ,Six Months Ended June ,Profit Margin ,Profit Attributable ,Net Profit Margin ,